Akeega (niraparib abiraterone acetate)

pCPA File Number: 22571
Negotiation Status:
Active Negotiation
Indication(s):
Akeega is indicated with prednisone or prednisolone for: The treatment of adult patients with deleterious or suspected deleterious BRCA mutated (germline and/or somatic) metastatic castration resistant prostate cancer (mCRPC), who are asymptomatic/mildly symptomatic, and in whom chemotherapy is not clinically indicated. Patients must have confirmation of BRCA mutation before Akeega treatment is initiated.
Sponsor/Manufacturer:
Janssen Inc.
CDA-AMC Project Number:
PC0326-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded:
Not Applicable